Item 8.01Other Events.

Story continues below

On August 11, 2017, Kindred Biosciences, Inc. (the “Company”) completed the closing of the exercise of the underwriters' option to purchase an additional 314,000 shares of common stock at the public offering price of $7.50 per share as part of the firm commitment underwritten offering that initially closed on July 17, 2017, resulting in additional gross proceeds to the Company of approximately $2.3 million. After giving effect to this exercise of the over-allotment option, the total number of shares sold by Company in the public offering increased to 3,314,000 shares and gross proceeds increased to approximately $24.8 million.

Ladenburg Thalmann & Co. Inc., a subsidiary ofLadenburg Thalmann Financial Services Inc.(NYSE MKT:LTS), acted as sole book-running manager and Aegis Capital Corp. acted as the lead manager. The shares were offered by the Company to an automatically effective shelf registration statement that was previously filed with the Securities and Exchange Commission (“SEC”). A prospectus supplement relating to, and describing the terms of, the offering was previously filed with the SEC and is available on the SEC’s web site at Copies of the prospectus supplement and the accompanying prospectus relating to the offering can be obtained from Ladenburg Thalmann, 277 Park Avenue, 26th Floor, New York, NY 10172 or by email at [email protected]

The information furnished under this Item 8.01 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liability of such section, nor shall such information be deemed to be incorporated by reference in any subsequent filing by the Company under the Securities Act of 1933 or the Exchange Act, regardless of the general incorporation language of such filing, except as specifically stated in such filing.


Kindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The Company is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company’s lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats. The Company’s other product candidates include KIND-010, KIND-014, KIND-015, KIND-510, KIND-502, KIND-0888, KIND-509, and several antibodies that target cytokines involved in atopic dermatitis.

An ad to help with our costs